Novartis Tabrecta Is First Treatment For NSCLC With METex14 Mutation

 
• By Jessica Merrill
  
lung cancer concept. doctor explaining results of lung check up from x-ray scan chest on digital tablet screen to patient.
Novartis' Tabrecta is approved by FDA for a NSCLC mutation • Source: Shutterstock
Scrip Podcast

Have you checked out Scrip podcast?

New episodes every Thursday.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip